48
Participants
Start Date
November 30, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
December 1, 2028
Acalabrutinib
Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
Rituximab
Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
RECRUITING
The Royal Bournemouth Hospital, Bournemouth
RECRUITING
University Hospital of Wales, Cardiff
RECRUITING
Royal Cornwall Hospital, Cornwall
RECRUITING
Beatson West of Scotland Cancer Centre, Glasgow
RECRUITING
St. Bartholomew's Hospital, London
RECRUITING
University College London Hospital, London
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
RECRUITING
Norfolk and Norwich University Hospital, Norwich
RECRUITING
Cancer and Haematology Centre, Churchill Hospital, Oxford
RECRUITING
Derriford Hospital, Plymouth
RECRUITING
Royal Stoke Hospital, Stoke-on-Trent
Collaborators (1)
AstraZeneca
INDUSTRY
University College, London
OTHER